CLINICAL & PIPELINE·Phase 3 Completion
GSK Shelves $2 Billion Camlipixant Chronic Cough Drug After Phase 3 Failure, Reshaping Market Dynamics
GSK has discontinued camlipixant's Phase 3 trials for chronic cough, shelving a drug acquired in a $2 billion deal. This failure, the third for a P2X3 antagonist, creates an 'open field opportunity' for Trevi Therapeutics' Haduvio, prompting a significant shift in the competitive landscape for respiratory treatments and re-emphasizing GSK's oncology focus.
90-Day Activity